In Vivo Gene Editing Market - 2026-2035
In Vivo Gene Editing Market reached US$ 2.46 billion in 2025 and is expected to reach US$ 37.75 billion by 2035, growing with a CAGR of 34.09% during the forecast period 2026-2035.
The In Vivo Gene Editing Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A In Vivo Gene Editing Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Editing Technology
Regional Analysis for In Vivo Gene Editing Market:
Both primary and secondary data sources have been used in the global In Vivo Gene Editing Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The In Vivo Gene Editing Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A In Vivo Gene Editing Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Editing Technology
- CRISPR*
- Cas9
- Cas12
- Cas13
- CRISPR Epigenetic Editing
- CRISPR RNA Targeting
- Base Editing
- Cytosine Base Editing
- Adenine Base Editing
- Dual Base Editing
- Prime Editing
- PE2
- PE3
- Next Generation Prime Editing
- TALEN
- Standard TALEN
- Engineered TALEN
- ZFN
- Modular ZFN
- Engineered ZFN
- RNA Editing
- ADAR-Based RNA Editing
- Cas13 RNA Editing
- Guide RNA Mediated RNA Editing
- Epigenome Editing
- DNA Methylation Editing
- Histone Modification Editing
- CRISPR Epigenetic Regulation
- Others
- Viral Vectors*
- AAV
- Adenoviral Vectors
- Lentiviral Vectors
- Non Viral Delivery
- Lipid Nanoparticles
- Polymer Nanoparticles
- Inorganic Nanoparticles
- Exosomes
- Extracellular Vesicles
- Peptide-Based Systems
- Ligand-Conjugated Delivery Systems
- GalNAc-Conjugated Systems
- Hybrid Nanoparticle Systems
- Virus Like Particles
- Others
- DNA*
- RNA
- Protein
- Ribonucleoprotein Complexes
- Intravenous *
- Intrathecal
- Intravitreal
- Intramuscular
- Subcutaneous
- Intratumoral
- Inhalation
- Local Injection
- Liver*
- Transthyretin Amyloidosis
- Hereditary Angioedema
- Hemophilia
- Primary Hyperoxaluria
- Familial Hypercholesterolemia
- Alpha-1 Antitrypsin Deficiency
- Eye
- Leber Congenital Amaurosis
- Retinitis Pigmentosa
- Stargardt Disease
- Age-Related Macular Degeneration
- Central Nervous System
- Huntington’s Disease
- Amyotrophic Lateral Sclerosis
- Parkinson’s Disease
- Alzheimer’s Disease
- Blood and Bone Marrow
- Lysosomal Storage Disorders
- Immunodeficiency Disorders
- Muscle
- Duchenne Muscular Dystrophy
- Limb-Girdle Muscular Dystrophy
- Myotonic Dystrophy
- Lung
- Cystic Fibrosis
- Pulmonary Fibrosis
- Heart
- Cardiomyopathy
- Transthyretin Amyloid Cardiomyopathy
- Inherited Cardiac Disorder
- Kidney
- Polycystic Kidney Disease
- Alport Syndrome
- Skin
- Epidermolysis Bullosa
- Genetic Skin Disorders
- Melanoma
- Others
- Rare Genetic Disorders*
- Duchenne Muscular Dystrophy
- Cystic Fibrosis
- Epidermolysis Bullosa
- Leber Congenital Amaurosis
- Lysosomal Storage Disorders
- Hematological Disorders
- Sickle Cell Disease
- Beta Thalassemia
- Hemophilia
- Fanconi Anemia
- Cardiometabolic and Liver Disorders
- Transthyretin Amyloidosis
- Hereditary Angioedema
- Familial Hypercholesterolemia
- Alpha-1 Antitrypsin Deficiency
- Primary Hyperoxaluria
- Wilson Disease
- Amyloid Cardiomyopathy
- Oncology
- Liver Cancer
- Lung Cancer
- Glioblastoma
- Hematologic Malignancies
- Solid Tumors
- Neurological Disorders
- Huntington’s Disease
- Parkinson’s Disease
- Amyotrophic Lateral Sclerosis
- Alzheimer’s Disease
- Spinal Muscular Atrophy
- Ophthalmic Disorders
- Retinitis Pigmentosa
- Stargardt Disease
- Age-Related Macular Degeneration
- Inherited Retinal Disorders
- Infectious Diseases
- Human Immunodeficiency Virus
- Hepatitis B
- Human Papillomavirus
- Herpes Simplex Virus
- Musculoskeletal Disorders
- Limb-Girdle Muscular Dystrophy
- Myotonic Dystrophy
- Osteogenesis Imperfecta
- Others
- Gene Knockout*
- Gene Correction
- Gene Insertion
- Gene Silencing
- Gene Activation
- Discovery*
- Preclinical
- Phase I
- Phase II
- Phase III
- Commercial
Regional Analysis for In Vivo Gene Editing Market:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global In Vivo Gene Editing Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Data
1.1.1. Secondary Data
1.1.2. Primary Data
1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations
2. DEFINITION AND OVERVIEW
2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period
3. EXECUTIVE SUMMARY
3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising demand for one time curative therapies is accelerating interest in in vivo gene editing
4.1.1.2. Strong clinical progress in liver and rare disease programs is improving market confidence
4.1.1.3. Advances in lipid nanoparticles and targeted delivery systems are expanding therapeutic potential
4.1.2. Restraints
4.1.2.1. Safe and precise delivery to target tissues remains the biggest bottleneck
4.1.2.2. Off target editing and immune response risks continue to slow broader adoption
4.1.3. Impact Analysis - Drivers and Restraints
4.1.4. Opportunity
4.1.4.1. Expansion into cardiometabolic and larger population diseases can unlock major revenue potential
4.1.4.2. Next generation platforms such as base editing and prime editing can widen the treatable disease pool
4.1.5. Trends
4.1.5.1. The market is shifting from conventional CRISPR toward more precise editing platforms
4.1.5.2. Delivery technology is becoming the main competitive differentiator in the market
4.1.6. Challenges
4.1.6.1. Achieving efficient extrahepatic delivery remains difficult
4.1.6.2. Managing long term safety and follow up requirements adds development burden
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors
5.3.1. Growing tenant and occupant expectations for comfort, indoor air quality, and seamless digital experiences are increasing retrofit demand
5.3.2. Facilities teams increasingly prefer integrated systems that reduce complexity instead of adding separate dashboards and controls
5.3.3. Adoption of automation improves when building staff can clearly see benefits in safety, maintenance efficiency, and occupant experience
5.4. Economic Factors
5.4.1. Fluctuating energy costs are strengthening the business case for automation, particularly across large buildings and multi-site portfolios
5.4.2. Incentives, energy efficiency mandates, and retrofit financing programs are supporting faster investment decisions
5.4.3. Building owners increasingly favor phased retrofit models that are funded through measurable operational savings
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Clinical Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion
6. BY EDITING TECHNOLOGY
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Editing Technology
6.1.2. Market Attractiveness Index, By Editing Technology
6.2. CRISPR*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Cas9
6.2.4. Cas12
6.2.5. Cas13
6.2.6. CRISPR Epigenetic Editing
6.2.7. CRISPR RNA Targeting
6.3. Base Editing
6.3.1. Cytosine Base Editing
6.3.2. Adenine Base Editing
6.3.3. Dual Base Editing
6.4. Prime Editing
6.4.1. PE2
6.4.2. PE3
6.4.3. Next Generation Prime Editing
6.5. TALEN
6.5.1. Standard TALEN
6.5.2. Engineered TALEN
6.6. ZFN
6.6.1. Modular ZFN
6.6.2. Engineered ZFN
6.7. RNA Editing
6.7.1. ADAR-Based RNA Editing
6.7.2. Cas13 RNA Editing
6.7.3. Guide RNA Mediated RNA Editing
6.8. Epigenome Editing
6.8.1. DNA Methylation Editing
6.8.2. Histone Modification Editing
6.8.3. CRISPR Epigenetic Regulation
6.9. Others
7. BY DELIVERY PLATFORM
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Platform
7.1.2. Market Attractiveness Index, By Delivery Platform
7.2. Viral Vectors*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. AAV
7.2.4. Adenoviral Vectors
7.2.5. Lentiviral Vectors
7.3. Non Viral Delivery
7.3.1. Lipid Nanoparticles
7.3.2. Polymer Nanoparticles
7.3.3. Inorganic Nanoparticles
7.3.4. Exosomes
7.3.5. Extracellular Vesicles
7.3.6. Peptide-Based Systems
7.3.7. Ligand-Conjugated Delivery Systems
7.3.8. GalNAc-Conjugated Systems
7.3.9. Hybrid Nanoparticle Systems
7.4. Virus Like Particles
7.5. Others
8. BY PAYLOAD TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Payload Type
8.1.2. Market Attractiveness Index, By Payload Type
8.2. DNA*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. RNA
8.4. Protein
8.5. Ribonucleoprotein Complexes
9. BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Intravenous *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intrathecal
9.4. Intravitreal
9.5. Intramuscular
9.6. Subcutaneous
9.7. Intratumoral
9.8. Inhalation
9.9. Local Injection
10. BY TARGET ORGAN
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Organ
10.1.2. Market Attractiveness Index, By Target Organ
10.2. Liver*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.2.3. Transthyretin Amyloidosis
10.2.4. Hereditary Angioedema
10.2.5. Hemophilia
10.2.6. Primary Hyperoxaluria
10.2.7. Familial Hypercholesterolemia
10.2.8. Alpha-1 Antitrypsin Deficiency
10.3. Eye
10.3.1. Leber Congenital Amaurosis
10.3.2. Retinitis Pigmentosa
10.3.3. Stargardt Disease
10.3.4. Age-Related Macular Degeneration
10.4. Central Nervous System
10.4.1. Huntington’s Disease
10.4.2. Amyotrophic Lateral Sclerosis
10.4.3. Parkinson’s Disease
10.4.4. Alzheimer’s Disease
10.5. Blood and Bone Marrow
10.5.1. Hemophilia
10.5.2. Lysosomal Storage Disorders
10.5.3. Immunodeficiency Disorders
10.6. Muscle
10.6.1. Duchenne Muscular Dystrophy
10.6.2. Limb-Girdle Muscular Dystrophy
10.6.3. Myotonic Dystrophy
10.7. Lung
10.7.1. Cystic Fibrosis
10.7.2. Alpha-1 Antitrypsin Deficiency
10.7.3. Pulmonary Fibrosis
10.8. Heart
10.8.1. Cardiomyopathy
10.8.2. Transthyretin Amyloid Cardiomyopathy
10.8.3. Inherited Cardiac Disorder
10.9. Kidney
10.9.1. Primary Hyperoxaluria
10.9.2. Polycystic Kidney Disease
10.9.3. Alport Syndrome
10.10. Skin
10.10.1. Epidermolysis Bullosa
10.10.2. Genetic Skin Disorders
10.10.3. Melanoma
10.11. Others
11. BY APPLICATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.1.2. Market Attractiveness Index, By Application
11.2. Rare Genetic Disorders*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.2.3. Duchenne Muscular Dystrophy
11.2.4. Cystic Fibrosis
11.2.5. Epidermolysis Bullosa
11.2.6. Leber Congenital Amaurosis
11.2.7. Lysosomal Storage Disorders
11.3. Hematological Disorders
11.3.1. Sickle Cell Disease
11.3.2. Beta Thalassemia
11.3.3. Hemophilia
11.3.4. Fanconi Anemia
11.4. Cardiometabolic and Liver Disorders
11.4.1. Transthyretin Amyloidosis
11.4.2. Hereditary Angioedema
11.4.3. Familial Hypercholesterolemia
11.4.4. Alpha-1 Antitrypsin Deficiency
11.4.5. Primary Hyperoxaluria
11.4.6. Wilson Disease
11.4.7. Amyloid Cardiomyopathy
11.5. Oncology
11.5.1. Liver Cancer
11.5.2. Lung Cancer
11.5.3. Glioblastoma
11.5.4. Hematologic Malignancies
11.5.5. Solid Tumors
11.6. Neurological Disorders
11.6.1. Huntington’s Disease
11.6.2. Parkinson’s Disease
11.6.3. Amyotrophic Lateral Sclerosis
11.6.4. Alzheimer’s Disease
11.6.5. Spinal Muscular Atrophy
11.7. Ophthalmic Disorders
11.7.1. Retinitis Pigmentosa
11.7.2. Stargardt Disease
11.7.3. Age-Related Macular Degeneration
11.7.4. Inherited Retinal Disorders
11.8. Infectious Diseases
11.8.1. Human Immunodeficiency Virus
11.8.2. Hepatitis B
11.8.3. Human Papillomavirus
11.8.4. Herpes Simplex Virus
11.9. Musculoskeletal Disorders
11.9.1. Duchenne Muscular Dystrophy
11.9.2. Limb-Girdle Muscular Dystrophy
11.9.3. Myotonic Dystrophy
11.9.4. Osteogenesis Imperfecta
11.10. Others
12. BY EDITING OUTCOME
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Editing Outcome
12.1.2. Market Attractiveness Index, By Route of Editing Outcome
12.2. Gene Knockout*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Gene Correction
12.4. Gene Insertion
12.5. Gene Silencing
12.6. Gene Activation
13. BY DEVELOPMENT STAGE
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development Stage
13.1.2. Market Attractiveness Index, By Route of Development Stage
13.2. Discovery*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Preclinical
13.4. Phase I
13.5. Phase II
13.6. Phase III
13.7. Commercial
14. BY END USER
1. INTRODUCTION
1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
1.1.1. Market Attractiveness Index, By End User
1.2. Biotechnology Companies*
1.2.1. Introduction
1.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
1.3. Pharmaceutical Companies
1.4. CDMOs
1.5. Academic and Research Institutes
1.6. Contract Research Organizations
1.7. Hospitals and Specialty Centers
2. BY REGION
2.1. Introduction
2.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
2.1.2. Market Attractiveness Index, By Region
2.2. North America*
2.2.1. Introduction
2.2.2. Key Region-Specific Dynamics
2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Editing Technology
2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Platform
2.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Payload Type
2.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
2.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Organ
2.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
2.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Editing Outcome
2.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development Stage
2.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
3. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY
3.1. U.S.
3.1.1. Canada
3.1.1.1. Mexico
3.2. Europe
3.2.1. Germany
3.2.1.1. UK
3.2.1.2. France
3.2.1.3. Russia
3.2.1.4. Spain
3.2.1.5. Italy
3.2.1.6. Poland
3.2.1.7. Rest of Europe
3.3. Latin America
3.3.1. Brazil
3.3.1.1. Argentina
3.3.1.2. Rest of Latin America
3.4. Asia-Pacific
3.4.1. China
3.4.1.1. India
3.4.1.2. Japan
3.4.1.3. Australia
3.4.1.4. South Korea
3.4.1.5. Indonesia
3.4.1.6. Malaysia
3.4.1.7. Rest of Asia-Pacific
3.5. Middle East and Africa
3.5.1. UAE
3.5.1.1. Saudi Arabia
3.5.1.2. South Africa
3.5.1.3. Israel
3.5.1.4. Turkiye
3.5.1.5. Rest of Middle East and Africa
4. COMPETITIVE LANDSCAPE
4.1. Competitive Scenario
4.2. Market Share Analysis - Global
4.3. Market Share Analysis - North America
4.4. Market Share Analysis - Europe
4.5. Market Share Analysis - Asia-Pacific
4.6. Mergers and Acquisitions Analysis
4.7. Partner Identification Analysis
4.8. Investment & Funding Landscape
4.9. Strategic Alliances & Innovation Pipeline
5. COMPANY PROFILES
5.1. Intellia Therapeutics, Inc.*
5.1.1. Company Overview
5.1.2. Product Portfolio and Description
5.1.3. Revenue Analysis
5.1.4. Pricing Analysis
5.1.5. SWOT Analysis
5.1.6. Recent Developments
5.1.6.1. Major Deals
5.1.6.2. M&A
5.1.6.3. Collaboration
5.1.6.4. Acquisition
5.1.6.5. Joint Ventures
5.1.6.6. Innovations
5.1.7. Recent News
5.1.7.1. Events
5.1.7.2. Conferences
5.1.7.3. Symposiums
5.1.7.4. Webinars
6. CRISPR THERAPEUTICS
6.1. Beam Therapeutics Inc.
6.2. Editas Medicine, Inc.
6.3. Prime Medicine, Inc.
6.4. Verve Therapeutics Inc.
6.5. Sangamo Therapeutics, Inc.
6.6. Precision BioSciences
6.7. Arbor Biotechnologies
6.8. Metagenomi Therapeutics, Inc.
6.9. Caribou Biosciences, Inc.
6.10. Regeneron Pharmaceuticals Inc.
6.11. Wave Life Sciences Ltd.
6.12. Korro Bio, Inc.
6.13. Mammoth Biosciences
6.14. Scribe Therapeutics
LIST NOT EXHAUSTIVE
1. APPENDIX
1.1. About Us and Services
1.2. Contact Us
Suggestions for Related Report
• Gene Editing Delivery Technologies Market (https://www.datamintelligence.com/research-report/gene-editing-delivery-technologies-market?utm_source=chatgpt.com)
• CRISPR Gene Editing Market (https://www.datamintelligence.com/research-report/crispr-gene-editing-market?utm_source=chatgpt.com)
• Genome Editing Market (https://www.datamintelligence.com/research-report/genome-editing-market)
• Gene Therapy Market (https://www.datamintelligence.com/research-report/gene-therapy-market)
• Cell and Gene Therapy Market (https://www.datamintelligence.com/research-report/cell-and-gene-therapy-market)
• Japan CRISPR-Cas9 Gene Editing Market (https://www.datamintelligence.com/research-report/japan-crispr-cas9-gene-editing-market)
• Viral Vector and Plasmid DNA Manufacturing Market (https://www.datamintelligence.com/research-report/viral-vector-and-plasmid-dna-manufacturing-market)
1.1. Research Data
1.1.1. Secondary Data
1.1.2. Primary Data
1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations
2. DEFINITION AND OVERVIEW
2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period
3. EXECUTIVE SUMMARY
3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising demand for one time curative therapies is accelerating interest in in vivo gene editing
4.1.1.2. Strong clinical progress in liver and rare disease programs is improving market confidence
4.1.1.3. Advances in lipid nanoparticles and targeted delivery systems are expanding therapeutic potential
4.1.2. Restraints
4.1.2.1. Safe and precise delivery to target tissues remains the biggest bottleneck
4.1.2.2. Off target editing and immune response risks continue to slow broader adoption
4.1.3. Impact Analysis - Drivers and Restraints
4.1.4. Opportunity
4.1.4.1. Expansion into cardiometabolic and larger population diseases can unlock major revenue potential
4.1.4.2. Next generation platforms such as base editing and prime editing can widen the treatable disease pool
4.1.5. Trends
4.1.5.1. The market is shifting from conventional CRISPR toward more precise editing platforms
4.1.5.2. Delivery technology is becoming the main competitive differentiator in the market
4.1.6. Challenges
4.1.6.1. Achieving efficient extrahepatic delivery remains difficult
4.1.6.2. Managing long term safety and follow up requirements adds development burden
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors
5.3.1. Growing tenant and occupant expectations for comfort, indoor air quality, and seamless digital experiences are increasing retrofit demand
5.3.2. Facilities teams increasingly prefer integrated systems that reduce complexity instead of adding separate dashboards and controls
5.3.3. Adoption of automation improves when building staff can clearly see benefits in safety, maintenance efficiency, and occupant experience
5.4. Economic Factors
5.4.1. Fluctuating energy costs are strengthening the business case for automation, particularly across large buildings and multi-site portfolios
5.4.2. Incentives, energy efficiency mandates, and retrofit financing programs are supporting faster investment decisions
5.4.3. Building owners increasingly favor phased retrofit models that are funded through measurable operational savings
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Clinical Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion
6. BY EDITING TECHNOLOGY
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Editing Technology
6.1.2. Market Attractiveness Index, By Editing Technology
6.2. CRISPR*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Cas9
6.2.4. Cas12
6.2.5. Cas13
6.2.6. CRISPR Epigenetic Editing
6.2.7. CRISPR RNA Targeting
6.3. Base Editing
6.3.1. Cytosine Base Editing
6.3.2. Adenine Base Editing
6.3.3. Dual Base Editing
6.4. Prime Editing
6.4.1. PE2
6.4.2. PE3
6.4.3. Next Generation Prime Editing
6.5. TALEN
6.5.1. Standard TALEN
6.5.2. Engineered TALEN
6.6. ZFN
6.6.1. Modular ZFN
6.6.2. Engineered ZFN
6.7. RNA Editing
6.7.1. ADAR-Based RNA Editing
6.7.2. Cas13 RNA Editing
6.7.3. Guide RNA Mediated RNA Editing
6.8. Epigenome Editing
6.8.1. DNA Methylation Editing
6.8.2. Histone Modification Editing
6.8.3. CRISPR Epigenetic Regulation
6.9. Others
7. BY DELIVERY PLATFORM
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Platform
7.1.2. Market Attractiveness Index, By Delivery Platform
7.2. Viral Vectors*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. AAV
7.2.4. Adenoviral Vectors
7.2.5. Lentiviral Vectors
7.3. Non Viral Delivery
7.3.1. Lipid Nanoparticles
7.3.2. Polymer Nanoparticles
7.3.3. Inorganic Nanoparticles
7.3.4. Exosomes
7.3.5. Extracellular Vesicles
7.3.6. Peptide-Based Systems
7.3.7. Ligand-Conjugated Delivery Systems
7.3.8. GalNAc-Conjugated Systems
7.3.9. Hybrid Nanoparticle Systems
7.4. Virus Like Particles
7.5. Others
8. BY PAYLOAD TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Payload Type
8.1.2. Market Attractiveness Index, By Payload Type
8.2. DNA*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. RNA
8.4. Protein
8.5. Ribonucleoprotein Complexes
9. BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Intravenous *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intrathecal
9.4. Intravitreal
9.5. Intramuscular
9.6. Subcutaneous
9.7. Intratumoral
9.8. Inhalation
9.9. Local Injection
10. BY TARGET ORGAN
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Organ
10.1.2. Market Attractiveness Index, By Target Organ
10.2. Liver*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.2.3. Transthyretin Amyloidosis
10.2.4. Hereditary Angioedema
10.2.5. Hemophilia
10.2.6. Primary Hyperoxaluria
10.2.7. Familial Hypercholesterolemia
10.2.8. Alpha-1 Antitrypsin Deficiency
10.3. Eye
10.3.1. Leber Congenital Amaurosis
10.3.2. Retinitis Pigmentosa
10.3.3. Stargardt Disease
10.3.4. Age-Related Macular Degeneration
10.4. Central Nervous System
10.4.1. Huntington’s Disease
10.4.2. Amyotrophic Lateral Sclerosis
10.4.3. Parkinson’s Disease
10.4.4. Alzheimer’s Disease
10.5. Blood and Bone Marrow
10.5.1. Hemophilia
10.5.2. Lysosomal Storage Disorders
10.5.3. Immunodeficiency Disorders
10.6. Muscle
10.6.1. Duchenne Muscular Dystrophy
10.6.2. Limb-Girdle Muscular Dystrophy
10.6.3. Myotonic Dystrophy
10.7. Lung
10.7.1. Cystic Fibrosis
10.7.2. Alpha-1 Antitrypsin Deficiency
10.7.3. Pulmonary Fibrosis
10.8. Heart
10.8.1. Cardiomyopathy
10.8.2. Transthyretin Amyloid Cardiomyopathy
10.8.3. Inherited Cardiac Disorder
10.9. Kidney
10.9.1. Primary Hyperoxaluria
10.9.2. Polycystic Kidney Disease
10.9.3. Alport Syndrome
10.10. Skin
10.10.1. Epidermolysis Bullosa
10.10.2. Genetic Skin Disorders
10.10.3. Melanoma
10.11. Others
11. BY APPLICATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.1.2. Market Attractiveness Index, By Application
11.2. Rare Genetic Disorders*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.2.3. Duchenne Muscular Dystrophy
11.2.4. Cystic Fibrosis
11.2.5. Epidermolysis Bullosa
11.2.6. Leber Congenital Amaurosis
11.2.7. Lysosomal Storage Disorders
11.3. Hematological Disorders
11.3.1. Sickle Cell Disease
11.3.2. Beta Thalassemia
11.3.3. Hemophilia
11.3.4. Fanconi Anemia
11.4. Cardiometabolic and Liver Disorders
11.4.1. Transthyretin Amyloidosis
11.4.2. Hereditary Angioedema
11.4.3. Familial Hypercholesterolemia
11.4.4. Alpha-1 Antitrypsin Deficiency
11.4.5. Primary Hyperoxaluria
11.4.6. Wilson Disease
11.4.7. Amyloid Cardiomyopathy
11.5. Oncology
11.5.1. Liver Cancer
11.5.2. Lung Cancer
11.5.3. Glioblastoma
11.5.4. Hematologic Malignancies
11.5.5. Solid Tumors
11.6. Neurological Disorders
11.6.1. Huntington’s Disease
11.6.2. Parkinson’s Disease
11.6.3. Amyotrophic Lateral Sclerosis
11.6.4. Alzheimer’s Disease
11.6.5. Spinal Muscular Atrophy
11.7. Ophthalmic Disorders
11.7.1. Retinitis Pigmentosa
11.7.2. Stargardt Disease
11.7.3. Age-Related Macular Degeneration
11.7.4. Inherited Retinal Disorders
11.8. Infectious Diseases
11.8.1. Human Immunodeficiency Virus
11.8.2. Hepatitis B
11.8.3. Human Papillomavirus
11.8.4. Herpes Simplex Virus
11.9. Musculoskeletal Disorders
11.9.1. Duchenne Muscular Dystrophy
11.9.2. Limb-Girdle Muscular Dystrophy
11.9.3. Myotonic Dystrophy
11.9.4. Osteogenesis Imperfecta
11.10. Others
12. BY EDITING OUTCOME
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Editing Outcome
12.1.2. Market Attractiveness Index, By Route of Editing Outcome
12.2. Gene Knockout*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Gene Correction
12.4. Gene Insertion
12.5. Gene Silencing
12.6. Gene Activation
13. BY DEVELOPMENT STAGE
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development Stage
13.1.2. Market Attractiveness Index, By Route of Development Stage
13.2. Discovery*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Preclinical
13.4. Phase I
13.5. Phase II
13.6. Phase III
13.7. Commercial
14. BY END USER
1. INTRODUCTION
1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
1.1.1. Market Attractiveness Index, By End User
1.2. Biotechnology Companies*
1.2.1. Introduction
1.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
1.3. Pharmaceutical Companies
1.4. CDMOs
1.5. Academic and Research Institutes
1.6. Contract Research Organizations
1.7. Hospitals and Specialty Centers
2. BY REGION
2.1. Introduction
2.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
2.1.2. Market Attractiveness Index, By Region
2.2. North America*
2.2.1. Introduction
2.2.2. Key Region-Specific Dynamics
2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Editing Technology
2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Platform
2.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Payload Type
2.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
2.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Organ
2.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
2.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Editing Outcome
2.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development Stage
2.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
3. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY
3.1. U.S.
3.1.1. Canada
3.1.1.1. Mexico
3.2. Europe
3.2.1. Germany
3.2.1.1. UK
3.2.1.2. France
3.2.1.3. Russia
3.2.1.4. Spain
3.2.1.5. Italy
3.2.1.6. Poland
3.2.1.7. Rest of Europe
3.3. Latin America
3.3.1. Brazil
3.3.1.1. Argentina
3.3.1.2. Rest of Latin America
3.4. Asia-Pacific
3.4.1. China
3.4.1.1. India
3.4.1.2. Japan
3.4.1.3. Australia
3.4.1.4. South Korea
3.4.1.5. Indonesia
3.4.1.6. Malaysia
3.4.1.7. Rest of Asia-Pacific
3.5. Middle East and Africa
3.5.1. UAE
3.5.1.1. Saudi Arabia
3.5.1.2. South Africa
3.5.1.3. Israel
3.5.1.4. Turkiye
3.5.1.5. Rest of Middle East and Africa
4. COMPETITIVE LANDSCAPE
4.1. Competitive Scenario
4.2. Market Share Analysis - Global
4.3. Market Share Analysis - North America
4.4. Market Share Analysis - Europe
4.5. Market Share Analysis - Asia-Pacific
4.6. Mergers and Acquisitions Analysis
4.7. Partner Identification Analysis
4.8. Investment & Funding Landscape
4.9. Strategic Alliances & Innovation Pipeline
5. COMPANY PROFILES
5.1. Intellia Therapeutics, Inc.*
5.1.1. Company Overview
5.1.2. Product Portfolio and Description
5.1.3. Revenue Analysis
5.1.4. Pricing Analysis
5.1.5. SWOT Analysis
5.1.6. Recent Developments
5.1.6.1. Major Deals
5.1.6.2. M&A
5.1.6.3. Collaboration
5.1.6.4. Acquisition
5.1.6.5. Joint Ventures
5.1.6.6. Innovations
5.1.7. Recent News
5.1.7.1. Events
5.1.7.2. Conferences
5.1.7.3. Symposiums
5.1.7.4. Webinars
6. CRISPR THERAPEUTICS
6.1. Beam Therapeutics Inc.
6.2. Editas Medicine, Inc.
6.3. Prime Medicine, Inc.
6.4. Verve Therapeutics Inc.
6.5. Sangamo Therapeutics, Inc.
6.6. Precision BioSciences
6.7. Arbor Biotechnologies
6.8. Metagenomi Therapeutics, Inc.
6.9. Caribou Biosciences, Inc.
6.10. Regeneron Pharmaceuticals Inc.
6.11. Wave Life Sciences Ltd.
6.12. Korro Bio, Inc.
6.13. Mammoth Biosciences
6.14. Scribe Therapeutics
LIST NOT EXHAUSTIVE
1. APPENDIX
1.1. About Us and Services
1.2. Contact Us
Suggestions for Related Report
• Gene Editing Delivery Technologies Market (https://www.datamintelligence.com/research-report/gene-editing-delivery-technologies-market?utm_source=chatgpt.com)
• CRISPR Gene Editing Market (https://www.datamintelligence.com/research-report/crispr-gene-editing-market?utm_source=chatgpt.com)
• Genome Editing Market (https://www.datamintelligence.com/research-report/genome-editing-market)
• Gene Therapy Market (https://www.datamintelligence.com/research-report/gene-therapy-market)
• Cell and Gene Therapy Market (https://www.datamintelligence.com/research-report/cell-and-gene-therapy-market)
• Japan CRISPR-Cas9 Gene Editing Market (https://www.datamintelligence.com/research-report/japan-crispr-cas9-gene-editing-market)
• Viral Vector and Plasmid DNA Manufacturing Market (https://www.datamintelligence.com/research-report/viral-vector-and-plasmid-dna-manufacturing-market)
